PDF(Pubmed)
Abstract：
BACKGROUND: Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 2 probably cannot tolerate chemotherapy or other antitumor therapies. Some studies have reported that immunotherapy combined with antiangiogenic therapy is well-tolerated and shows good antitumor activity. However, the efficacy of this combination as a later-line therapy in patients with ECOG PS 2 is unclear. This study evaluated the effectiveness and safety of this combination strategy as third- or further-line therapy in stage IV non-small cell lung cancer (NSCLC) patients with ECOG PS 2.
METHODS: In this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.
RESULTS: Between January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow-up of 10.5 months (range: 0.7-23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8-7.3) and the median OS was 10.5 months (95% CI: 11.2-13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3-4 treatment-related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment-related deaths.
CONCLUSIONS: Third- or further-line immunotherapy combined with antiangiogenic therapy is well-tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large-scale prospective studies are required to confirm the clinical benefits of this combination therapy.
METHODS: In this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.
RESULTS: Between January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow-up of 10.5 months (range: 0.7-23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8-7.3) and the median OS was 10.5 months (95% CI: 11.2-13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3-4 treatment-related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment-related deaths.
CONCLUSIONS: Third- or further-line immunotherapy combined with antiangiogenic therapy is well-tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large-scale prospective studies are required to confirm the clinical benefits of this combination therapy.
摘要：
背景：东部肿瘤协作组表现状态（ECOGPS）2的患者可能不能耐受化疗或其他抗肿瘤治疗。一些研究报道，免疫疗法与抗血管生成疗法相结合具有良好的耐受性，并显示出良好的抗肿瘤活性。然而,这种联合疗法作为ECOGPS2患者的后期治疗的疗效尚不清楚.这项研究评估了这种联合治疗策略作为第三线或进一步治疗IV期非小细胞肺癌（NSCLC）患者ECOGPS2的有效性和安全性。
方法：在这项回顾性研究中，卡姆瑞珠单抗联合抗血管生成治疗的患者(贝伐单抗，安洛替尼,或重组人内皮抑素）包括在内。客观反应率（ORR），疾病控制率（DCR），无进展生存期（PFS），总生存期（OS），通过ECOGPS评估生活质量（QOL），并对安全性进行了分析。
结果：在2019年1月10日至2024年2月28日之间，共包括59例患者。ORR为35.6%(21/59),DCR为86.4%。中位随访时间为10.5个月（范围：0.7-23.7），中位PFS为5.5个月(95%置信区间[CI]:3.8~7.3),中位OS为10.5个月(95%CI:11.2~13.6).39例（66.1%）患者的生活质量得到改善（ECOGPS降低≥1）。最常见的3-4级治疗相关不良事件是肝功能障碍（6[10%]），高血压（5[8%]），和甲状腺功能减退（3[5%]）。没有治疗相关的死亡。
结论：三线或进一步的免疫治疗联合抗血管生成治疗在患有ECOGPS2的IV期NSCLC患者中具有良好的耐受性和良好的抗肿瘤活性。未来需要大规模的前瞻性研究来证实这种联合治疗的临床益处。
方法：在这项回顾性研究中，卡姆瑞珠单抗联合抗血管生成治疗的患者(贝伐单抗，安洛替尼,或重组人内皮抑素）包括在内。客观反应率（ORR），疾病控制率（DCR），无进展生存期（PFS），总生存期（OS），通过ECOGPS评估生活质量（QOL），并对安全性进行了分析。
结果：在2019年1月10日至2024年2月28日之间，共包括59例患者。ORR为35.6%(21/59),DCR为86.4%。中位随访时间为10.5个月（范围：0.7-23.7），中位PFS为5.5个月(95%置信区间[CI]:3.8~7.3),中位OS为10.5个月(95%CI:11.2~13.6).39例（66.1%）患者的生活质量得到改善（ECOGPS降低≥1）。最常见的3-4级治疗相关不良事件是肝功能障碍（6[10%]），高血压（5[8%]），和甲状腺功能减退（3[5%]）。没有治疗相关的死亡。
结论：三线或进一步的免疫治疗联合抗血管生成治疗在患有ECOGPS2的IV期NSCLC患者中具有良好的耐受性和良好的抗肿瘤活性。未来需要大规模的前瞻性研究来证实这种联合治疗的临床益处。
